Michael Girardi, MD
Dermatology · New Haven, CTNPI 1154302842
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,285 of the $19,848 with a category attached, or 97.2%. 9 manufacturers reported payments, led by Helsinn Therapeutics (U.S.), Inc. at 30.7% of the total. Reporting peaked in 2019 at $10,470 and has fallen 76.1% since, to $2,502 in 2025.
Across 13 payments — averaging $1526.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Helsinn Therapeutics (U.S.), Inc.$6K
- Sanofi-aventis U.S. LLC$4K
- Mallinckrodt Hospital Products Inc.$4K
- LEO Pharma Inc.$3K
- Therakos LLC$2K
- Kyowa Kirin, Inc.$275
- plus $266 from 3 others
Across 13 payments — averaging $31,102 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$365K
- Mallinckrodt Hospital Products Inc.$39K
What the payments were for
- Consulting fees$19,28597%
- Food & beverage$5413%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Helsinn Therapeutics (U.S.), Inc. | 1 | $6,100 |
| Sanofi-aventis U.S. LLC | 1 | $4,230 |
| Mallinckrodt Hospital Products Inc. | 2 | $3,900 |
| LEO Pharma Inc. | 1 | $2,715 |
| Therakos LLC | 2 | $2,362 |
| Kyowa Kirin, Inc. | 2 | $275 |
| Mallinckrodt Enterprises LLC | 2 | $140 |
| Sun Pharmaceutical Industries Inc. | 1 | $108 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALCHLOR$6,100
- NO PRODUCT DISCUSSED$4,230
- UVADEX$3,900
- POTELIGEO$275
- ILUMYA$108
How this compares
$19,848 in reported general payments places this provider in the 85th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bexarotene | 15 | $165,714 |
| Dupixent PenDupilumab | 17 | $64,586 |
| Dupixent SyringeDupilumab | 13 | $62,716 |
| Econazole Nitrate | 18 | $2,960 |
| Clobetasol Propionate | 68 | $2,536 |
| Triamcinolone Acetonide | 69 | $1,105 |
| Ketoconazole | 61 | $704 |
| Hydrocortisone | 20 | $214 |
| Levothyroxine Sodium | 15 | $191 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New Haven
- Christopher BunickNew Haven$661K
- Keith ChoateNew Haven$362K
- David LeffellNew Haven$94K
- Mariam TotonchyNew Haven$52K
- Lisa DonofrioNew Haven$38K
- Richard AntayaNew Haven$37K
- Leonard MilstoneNew Haven$31K
- William DamskyNew Haven$23K
- Jeffrey CohenNew Haven$18K
- Mary TomaykoNew Haven$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.